Sichuan Biokin Pharmaceutical Co., Ltd.: Business Overview, Financials & Competitive Analysis
Sichuan Biokin Pharmaceutical Co., Ltd. scores 7/10 on the AskCyborg Cyborg Score (Strong). Compelling positioned platform company with diversified revenue streams transitioning toward higher-value oncology therapeutics while maintaining cash-generative generic business. Biokin demonstrates strong fundamentals with integrated operations, dual business models balancing near-term generic revenue with high-potential innovative drug development, and strategic presence in global markets. However, negative trailing EPS.
What is Sichuan Biokin Pharmaceutical Co., Ltd.'s industry? Sichuan Biokin Pharmaceutical Co., Ltd. (baili-pharm.com) operates in Biopharmaceuticals / Specialty Pharmaceuticals. AskCyborg classifies Sichuan Biokin Pharmaceutical Co., Ltd. under Biopharmaceuticals / Specialty Pharmaceuticals in its company registry.
Sichuan Biokin Pharmaceutical is a vertically integrated biopharmaceutical company founded in 1996 that combines research and development, manufacturing, and commercialization across small molecule, biological, and an...
Cyborg Score thesis
Compelling positioned platform company with diversified revenue streams transitioning toward higher-value oncology therapeutics...
Read the full analyst-debate transcript →Get the Latest Sichuan Biokin Pharmaceutical Co., Ltd. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeSichuan Biokin Pharmaceutical Co., Ltd. Overview
Pro stress-test →Sichuan Biokin Pharmaceutical is a vertically integrated biopharmaceutical company founded in 1996 that combines research and development, manufacturing, and commercialization across small molecule, biological, and antibody-drug conjugate platforms. The company operates dual business segments: established generic pharmaceutical operations generating current revenue and innovative biological drug development targeting oncology for Chinese, Asian, European and American markets.
Strategic Profile
Pro stress-test →Biokin leverages an integrated platform spanning R&D centers in both China and the United States (through subsidiary SystImmune, Inc.), proprietary tumor antibody drug development capabilities, and comprehensive manufacturing infrastructure including biological drug production and multiple formulation facilities. The company's competitive advantage lies in its full-spectrum value chain integration—from discovery through commercialization—combined with recognized expertise in pediatric medicines and a strong intellectual property portfolio.
Competitive Landscape
Pro stress-test →Biokin competes in China's fragmented pharmaceutical market against major domestic generics producers (e.g., China Biologic Products, China National Pharmaceutical Group) and increasingly against innovative biotech firms developing monoclonal antibodies and ADCs. The company's differentiation is its integrated model combining generic cash flow with advanced antibody development platforms—relatively rare in China. Global competitors include established ADC developers like Seagen/Pfizer and emerging Chinese biotech players entering oncology.
Industry Context
Sichuan Biokin Pharmaceutical Co., Ltd. operates in Biopharmaceuticals / Specialty Pharmaceuticals.
Key facts
Founded: 1996 · Headquarters: Chengdu, China · Employees: 2521 · Market cap: 154.49B CNY